Eevia Health Plc receives a 230 KSEK/21 KEUR starting sales order for a new Lingonberry product to a new customer
Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.
The end customer, which is new to Eevia, is a major natural health company based out of Sydney, Australia selling its consumer products across Oceania. The sales value to Eevia of this new order is c. 21 000 EUR. The product is a Lingonberry extract that contains bioactive proanthocyanidins, a bioactive compound often referred to in the nutraceutical industry called PACs. Eevia's distributor, Ingredients Plus, serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients.
The Lingonberry powder from Eevia is produced for the first time using Gum Arabic Acacia in the spray drying process, which provides an additional unique selling point. Gum Arabic is based on high molecular polysaccharides obtained from the stems and branches of Acacia bushes. It allows customers to use an ingredient without the use of maltodextrin, which is unpopular in consumer groups focused on organic products.
"Although this is only a small start order which takes less than a day to produce, I am extremely excited to see that we are succeeding in developing sales of the Lingonberry products and to reach new customers. The Lingonberry from northern Sweden and Finland is just an amazing raw material source. The Arctic Lingonberry has numerous unique properties. It has natural anti-microbial effects, and high concentrations of proanthocyanidins, two more than the four proanthocyanidins you get from Cranberry. This evergreen plan provides a very stable biomass of fruit year after year. The Swedish and Finnish forests produce more than a million tons of Lingonberries. We are picking only a tiny fraction of that. It tastes good, looks good with vibrant red color, and with its strong health benefits, we have the potential to cannibalize a large cranberry market and also other segments with a superior product" says Stein Ulve, CEO of Eevia Health.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: [email protected]
Telephone: +358 400 22 5967
Gabriella Beni, CFO, Eevia Health Plc
Email: [email protected]
Telephone: +358 407 48 8666
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Eevia Health ("Eevia" or "The Company") received a start order for the Feno-Sambucus™ worth SEK 110 000 from its Australian distributor Ingredient Plus. The order is a new start order for an Australian brand owner.
Eevia Health Plc's ("Eevia" or "The Company") has received a 41 KEUR sales order for Bilberry extract from its distributor in France Natural Ingredients.
Eevia Health has commissioned a new High-Performance Liquid Chromatography (HPLC) analytical equipment from Shimadzu, which significantly increases the capacity to undertake analyses of polyphenols.
Eevia Health Plc, ("Eevia" or "The Company"), has re-established its Kosher certification. The Jewish Community of Helsinki has validated Eevia's Kosherization and certified the Kosher and Parve status of the company products.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the third quarter of 2022.
Eevia Health Plc ("Eevia" och "the Company") announces today the outcome of the Rights Issue, whose subscription period ended on November 15, 2022, where a total of 14 376 015 shares, corresponding to 100 percent of the offered shares, have been allocated. 9 233 685 shares (64 percent) were subscribed with subscription rights, and 5 142 330 shares (36 percent) were subscribed without subscription rights, corresponding to 100 percent of the Rights Issue. Through the Rights Issue, the Company will raise proceeds of approximately SEK 21.6 million before deducting costs related to the Rights Issue. No guaranteed commitments have been utilized.
To timely secure raw materials for its recent order intake of large quantities of bilberry products, Eevia Health Plc ("Eevia" or "The Company") has secured a short-term loan of NOK 2 million from its largest shareholder, Betulum AS (Norway).
Eevia Health Plc received its first sales order for its new cognitive health ingredient product, Feno-Cerasus™, made from the tart cherry of SEK 223k
Following a successful exhibition at the Supply Side West trade show in Las Vegas, US, last week, Eevia Health received a start order for its new cognitive health product, the Feno-Cerasus™, for SEK 223k. The new product was launched last week and is a standardized anthocyanin extract from tart cherry (Prunus Cerasus). Eevia Health focuses on the cognitive effects of the latest product, including sleep quality and quantity, memory, stress, and cortisol levels.
Eevia Health Plc received new sales order for Feno-Sambucus™ for the equivalent of c. SEK 34.4 million
Following a successful exhibition at the Supply Side West trade show in Las Vegas, US, last week, Eevia Health ("Eevia" or "The Company") received an order for the Feno-Sambucus™ equaling a revenue of SEK 34.4 million. The order is a new contractual volume section related to a five-year Sales Agreement with a US brand owner. The new section has adjusted prices and terms.
Eevia Health Plc launches a new dietary supplement ingredient, Feno-Cerasus™, for cognitive health at a key industry trade show, Supply Side West in Las Vegas, US
Eevia Health has developed a new plant extract with product benefits for cognitive health and improved sleep. The new product, Feno-Cerasus™, is launched today at a major trade show in Las Vegas, US, the Supply Side West. The new ingredient is a standardized anthocyanin extract from tart cherry (Prunus Cerasus). Eevia Health focuses on the cognitive effects of the new products, including sleep quality and quantity, memory, as well as stress, and cortisol levels.
Eevia Health Plc